NeuroTimone Facility (PFNT)

The PFNT Facility is a coherent set of exploration tools in neurobiology allowing research at the molecular, cellular and integrated levels.

News

  1. GlioME team and PETRA"TECH" platform: a new paper is out in Neuro-Oncology!

    Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.

  2. Emeline Tabouret from the GlioME Team discussed data from trials during the proffered paper session – CNS tumours at the ESMO Congress 2024 (13-17 September, Barcelona, Spain)
  3. ERC Starting Grant for the SynapTau team

    Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.

    We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.

    We look forward to sharing this moment with you!

  4. NeuroCyto team in Science: the unique architecture of axonal endocytosis

    We’re over the moon to see our latest work with Stéphane Vassilopoulos and his team published in Science. Check out how we reveal the unique architecture of clathrin-coated pits and endocytosis at the axon initial segment!

  5. INP teams attending Canceropole 11th Annual Seminar

    Comme chaque année les équipes 8, 9 et 10 de l’INP ont participé au Séminaire Annuel du Canceropôle qui se tenait au Palais des Congrès de Saint-Raphaël les 4 et 5 juillet 2024.

  6. Chiara received a prize for the best master’s thesis

    Congratulations to Chiara Bordier (team 2 SynapTau) for receiving the GBM (Association for Biochemistry and Molecular Biology) Master Prize for the best master’s thesis! This year, Professor Lichtenthaler from Technische Universität München and the DZNE presented this honour, marking the fourth time it has been awarded. Chiara's award-winning research explored the impact of Tau protein on nuclear organization and chromatin dynamics in neurodegenerative diseases, highlighting its crucial role in nuclear tension and stress response.

  7. INP & VH invited to the "Imagining the futur of cancer treatments" symposium

    INP and Vect-Horus both participated to the symposium “Imagining the future of cancer treatments” (~100 participants) organized by the Translate-It departement of CRCM in Luminy. Along with keynote speaker Maria Kavallaris (Director of the Australian Centre for NanoMedicine at UNSW), François Devred gave an overview of INP's work on cancer entitle "How the INP contributes to the future of cancer treatments" and Pavlo Shpak-Kraievskyi of Vect-Horus gave a talk on "Surface modification of LNPs for brain targeting of nucleic acids"

  8. 3 INP PhD students at the FENS 2024

    Sofia (PhD student team 7), Charbel (PhD student teams 3 and 9) and Jehanne (PhD student team 5) attended and presented posters at FENS 2024 in Vienna (Austria). It was an enriching experience to discuss their work with their peers, attend presentations on innovative research in our respective fields, and enjoy typical Austrian dishes with other members of NeuroMarseille and beyond. 

Pages

INP in numbers

  • 126 members
  • 44 researchers
  • 48 research assistants
  • 12 post-docs
  • 11 PhD

 

GlioME team and PETRA"TECH" platform: a new paper is out in Neuro-Oncology!

Because generation of patient avatar for preclinical therapeutic development is critically needed in neuro-oncology, the GlioME team in collaboration with the PETRA"TECH" platform developed an easy method to generate tumoroids from primary and metastatic brain tumors, including a dedicated 3D spatial analysis workflow for drug development.

Undefined

Emeline Tabouret from the GlioME Team discussed data from trials during the proffered paper session – CNS tumours at the ESMO Congress 2024 (13-17 September, Barcelona, Spain)

Three presentations at the ESMO Congress 2024 (Barcelona, 13–17 September) reported on therapies designed to stimulate or boost the body’s antitumour immune response in the management of aggressive, high-grade gliomas, which typically carry a poor prognosis.

Emeline Tabouret from GlioME Team discussed these data during the proffered paper session – CNS tumours reported here.

 

English

ERC Starting Grant for the SynapTau team

Maud, Chiara, and Matthew (SynapTau team) are happy to announce the award of an ERC Starting Grant for the team, with the project set to begin in January 2025. The ERC project "SynApoE" aims to characterize how ApoE4 controls synaptic degeneration in Alzheimer's disease.

We invite you to celebrate this great news on September 23rd, during Maud's HDR celebration.

We look forward to sharing this moment with you!

Undefined

Chiara received a prize for the best master’s thesis

Congratulations to Chiara Bordier (team 2 SynapTau) for receiving the GBM (Association for Biochemistry and Molecular Biology) Master Prize for the best master’s thesis! This year, Professor Lichtenthaler from Technische Universität München and the DZNE presented this honour, marking the fourth time it has been awarded. Chiara's award-winning research explored the impact of Tau protein on nuclear organization and chromatin dynamics in neurodegenerative diseases, highlighting its crucial role in nuclear tension and stress response.

Undefined

Partners